CoChat

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Purpose Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulated paclitaxel (Taxol) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. Methods A total of 35 patients (average +/- SD age: 59 +/-13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m(2) paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC-MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. Results A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 +/- 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Conclusions Population pharmacokinetic analysis indicated linear disposition and a pote…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00280-008-0827-2

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 1

  1. Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM Users Guides (1989–2006). Icon Development Solutions, Ellicott City

Cited by

Metadata

Authors
Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J.
Affiliations
  • University at Buffalo, State University of New York (US)
  • University of Georgia (US)
  • Asklepios Klinik St. Georg (DE)
  • Leiden University Medical Center (NL)
  • Institut Jules Bordet (BE)
Corresponding author
Jusko, William J.
Venue
Cancer Chemotherapy and Pharmacology
Published
2008-09-13
Volume
63
Issue
6
Pages
1049-1063
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2089920524
Cited by
47
References
45
Citations by year
2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 5
FWCI
0.88
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
paclitaxel, Cremophor EL, population pharmacokinetic model, drug release kinetics, bioavailability, infusion duration, non-hematological malignancies
MeSH terms
Adult, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Chromatography, Liquid, Female, Humans, Leukocyte Count, Male, Middle Aged, Models, Biological, Monte Carlo Method, Neoplasms, Structure-Activity Relationship, Tissue Distribution, Linear Models, Drug Delivery Systems, Paclitaxel, Cross-Over Studies, Tandem Mass Spectrometry, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.